Online inquiry

IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14025MR)

This product GTTS-WQ14025MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14025MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9519MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ3889MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ11805MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ10792MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ13499MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ10251MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ798MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ1861MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW